Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Immunogen Inc's Business Segments
Immunogen Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 113
Regions Reported
-
Immunogen Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product Revenue Net92.7%
- Noncash Royalty Revenue Related to Sale of Future Royalties6.5%
- Research and Development Support0.8%
- License and Milestone Fees0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product Revenue Net | $ 105 | 92.7% |
| Noncash Royalty Revenue Related to Sale of Future Royalties | $ 7 | 6.5% |
| Research and Development Support | $ 1 | 0.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Immunogen Inc dataset.
Description of Immunogen Inc
Immunogen Inc. is a biotechnology company that specializes in the development of targeted cancer therapies. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Immunogen's core technology is its Antibody Drug Conjugate (ADC) technology, which involves combining potent cancer cell-killing agents called cytotoxic agents with cancer-targeting antibodies. The resulting ADCs are designed to selectively bind to cancer cells, delivering the cytotoxic agents directly to the cancer cells and minimizing damage to healthy cells. This targeted approach aims to improve the efficacy and safety of cancer treatments.
Immunogen has a long history of developing ADCs and its technology platform has been used to develop several clinical-stage products, including mirvetuximab soravtansine, IMGN779, IMGN632, and IMGN15 Mirvetuximab soravtansine is a promising product that targets folate receptor alpha (FRα), which is found on the surface of various types of cancer cells, including ovarian cancer. The drug has demonstrated clinical activity in patients with FRα-positive ovarian cancer and is currently in Phase 3 clinical trials.
In addition to its internal pipeline, Immunogen partners with other companies to develop ADCs using its technology. Some of its notable partnerships include collaborations with Roche, Sanofi, and Takeda.
Immunogen has a strong intellectual property portfolio, with numerous patents covering its ADC technology and processes. The company's technology and products have been recognized with numerous awards and accolades, including the Galien Foundation's Best Biotechnology Product award and the Boston Business Journal's Best Places to Work award.
Overall, Immunogen Inc. is a leader in the development of targeted cancer therapies, with a strong focus on ADCs. Its technology platform and extensive pipeline make it a promising company in the biotechnology industry.
Immunogen's core technology is its Antibody Drug Conjugate (ADC) technology, which involves combining potent cancer cell-killing agents called cytotoxic agents with cancer-targeting antibodies. The resulting ADCs are designed to selectively bind to cancer cells, delivering the cytotoxic agents directly to the cancer cells and minimizing damage to healthy cells. This targeted approach aims to improve the efficacy and safety of cancer treatments.
Immunogen has a long history of developing ADCs and its technology platform has been used to develop several clinical-stage products, including mirvetuximab soravtansine, IMGN779, IMGN632, and IMGN15 Mirvetuximab soravtansine is a promising product that targets folate receptor alpha (FRα), which is found on the surface of various types of cancer cells, including ovarian cancer. The drug has demonstrated clinical activity in patients with FRα-positive ovarian cancer and is currently in Phase 3 clinical trials.
In addition to its internal pipeline, Immunogen partners with other companies to develop ADCs using its technology. Some of its notable partnerships include collaborations with Roche, Sanofi, and Takeda.
Immunogen has a strong intellectual property portfolio, with numerous patents covering its ADC technology and processes. The company's technology and products have been recognized with numerous awards and accolades, including the Galien Foundation's Best Biotechnology Product award and the Boston Business Journal's Best Places to Work award.
Overall, Immunogen Inc. is a leader in the development of targeted cancer therapies, with a strong focus on ADCs. Its technology platform and extensive pipeline make it a promising company in the biotechnology industry.
Immunogen, Inc. based in Waltham, Massachusetts, is a biotechnology company recognized for its commitment to developing targeted cancer therapies aimed at delivering new treatments that improve patient outcomes. The company focuses on leveraging its proprietary antibody-drug conjugate (ADC) technology, which allows for the precise targeting of cancer cells while minimizing damage to healthy tissues.
Segments
1. Targeted Cancer Therapies
This segment is the cornerstone of Immunogens operations, concentrating on the invention and development of new ADCs that can effectively target and destroy cancer cells. This approach is designed to enhance the efficacy of treatments while reducing systemic toxicity, a common issue with traditional chemotherapy.
Collaboration and Licensing
Immunogen actively engages in partnerships with other biotechnology and pharmaceutical firms. By collaborating with industry leaders and innovators, Immunogen seeks to expand its reach and harness complementary technologies and expertise. The company licenses its ADC technology to other entities, enabling them to develop and commercialize new cancer therapies utilizing Immunogens innovative platform.
Products
1. Mirvetuximab Soravtansine (IMGN853)
Currently the most advanced product candidate from Immunogen, Mirvetuximab Soravtansine, is designed for the treatment of ovarian cancer. This ADC specifically targets the folate receptor alpha (FRe), which is abundantly expressed in various ovarian cancer cells. The drug has shown promise in clinical trials, demonstrating the potential to provide effective, targeted therapy for patients with this challenging condition.
IMGN779
IMGN779 is another significant development from Immunogen, targeting CD33—a cell surface protein prevalent in myeloid leukemia cells. The product is being investigated as a treatment for acute myeloid leukemia (AML). IMGN779 aims to deliver cytotoxic agents directly to the cancer cells, sparing normal cells and thereby reducing side effects associated with conventional therapies.
IMGN632
This ADC targets CD123, a marker found on many leukemic cells and blastic plasmacytoid dendritic cell neoplasm (BPDCN). The specificity of IMGN632 for CD123 could allow for more effective treatments for patients suffering from AML and BPDCN. The ongoing studies aim to evaluate its safety and efficacy in clinical settings.
Services
1. ADC Technology Platform
Immunogen provides access to its proprietary ADC technology platform, which includes the mechanistic insights and technological capabilities necessary to develop targeted cancer therapies. This platform encompasses a variety of tools and resources, allowing partners to design ADCs tailored to their specific needs and targets.
Expertise in Research and Development
The company boasts a highly knowledgeable research and development team specialized in oncology. This team offers technical support and guidance to partners, assisting them in navigating the complexities of drug discovery, clinical development, and regulatory processes. Immunogen’s extensive experience in the field positions it as a valuable ally for companies looking to advance their oncology products.
In summary, Immunogen, Inc. operates through two main segments—Targeted Cancer Therapies and Collaboration and Licensing. The company focuses on the development of innovative ADCs like Mirvetuximab Soravtansine, IMGN779, and IMGN632, each targeting specific cancer-related proteins. Additionally, Immunogen provides services including access to its ADC technology platform and extensive research and development expertise, aimed at advancing the landscape of targeted cancer treatments. This dedicated approach underscores Immunogens commitment to providing effective solutions for cancer patients.
Segments
1. Targeted Cancer Therapies
This segment is the cornerstone of Immunogens operations, concentrating on the invention and development of new ADCs that can effectively target and destroy cancer cells. This approach is designed to enhance the efficacy of treatments while reducing systemic toxicity, a common issue with traditional chemotherapy.
Collaboration and Licensing
Immunogen actively engages in partnerships with other biotechnology and pharmaceutical firms. By collaborating with industry leaders and innovators, Immunogen seeks to expand its reach and harness complementary technologies and expertise. The company licenses its ADC technology to other entities, enabling them to develop and commercialize new cancer therapies utilizing Immunogens innovative platform.
Products
1. Mirvetuximab Soravtansine (IMGN853)
Currently the most advanced product candidate from Immunogen, Mirvetuximab Soravtansine, is designed for the treatment of ovarian cancer. This ADC specifically targets the folate receptor alpha (FRe), which is abundantly expressed in various ovarian cancer cells. The drug has shown promise in clinical trials, demonstrating the potential to provide effective, targeted therapy for patients with this challenging condition.
IMGN779
IMGN779 is another significant development from Immunogen, targeting CD33—a cell surface protein prevalent in myeloid leukemia cells. The product is being investigated as a treatment for acute myeloid leukemia (AML). IMGN779 aims to deliver cytotoxic agents directly to the cancer cells, sparing normal cells and thereby reducing side effects associated with conventional therapies.
IMGN632
This ADC targets CD123, a marker found on many leukemic cells and blastic plasmacytoid dendritic cell neoplasm (BPDCN). The specificity of IMGN632 for CD123 could allow for more effective treatments for patients suffering from AML and BPDCN. The ongoing studies aim to evaluate its safety and efficacy in clinical settings.
Services
1. ADC Technology Platform
Immunogen provides access to its proprietary ADC technology platform, which includes the mechanistic insights and technological capabilities necessary to develop targeted cancer therapies. This platform encompasses a variety of tools and resources, allowing partners to design ADCs tailored to their specific needs and targets.
Expertise in Research and Development
The company boasts a highly knowledgeable research and development team specialized in oncology. This team offers technical support and guidance to partners, assisting them in navigating the complexities of drug discovery, clinical development, and regulatory processes. Immunogen’s extensive experience in the field positions it as a valuable ally for companies looking to advance their oncology products.
In summary, Immunogen, Inc. operates through two main segments—Targeted Cancer Therapies and Collaboration and Licensing. The company focuses on the development of innovative ADCs like Mirvetuximab Soravtansine, IMGN779, and IMGN632, each targeting specific cancer-related proteins. Additionally, Immunogen provides services including access to its ADC technology platform and extensive research and development expertise, aimed at advancing the landscape of targeted cancer treatments. This dedicated approach underscores Immunogens commitment to providing effective solutions for cancer patients.